Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort
Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101307
DOI: 10.1016/j.ctro.2026.101307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Tina Bockstiegel und 44 weiteren Autor:innen. Beteiligte Einrichtung: Mannheim Comprehensive Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Generalitat de Catalunya, Albert Einstein Cancer Center, NIHR Leicester Biomedical Research Centre.
Abstract (Originalsprache)
Purpose
The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects.
Methods
Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at inclusion, no other malignancy within the previous five years, and no prior breast irradiation. Blood samples were collected before radiotherapy for genotyping, molecular analysis, and biobanking. Standardised assessments included CTCAE v4, EORTC QLQ-C30 and BR23, MFI, GPAQ, and DICOM/DVH data. Follow-up continued annually for two years, extending to eight years at eligible sites.
Results
Acute side effects peaked at end of radiotherapy, with erythema in 83-89% of patients. Grade ≥ 2 acute effects, including pain (11% versus 4.3%) and skin ulceration (4.8% versus 0.8%), were more frequent with normofractionation than hypofractionation. Grade ≥ 2 late effects affected between 0.6% and 16.8% of patients; skin induration was the most frequent late effect. Patient-reported outcome scores varied over time, with functional scale scores at two years similar to or higher than at baseline.
Conclusion
REQUITE provides real-world evidence of acute and late outcomes following normo- and hypofractionation, broadly consistent with published randomised trials. The dataset, combining clinical adverse effects, quality of life, dosimetric, and genetic data, is a resource for personalised radiotherapy research (www.requite.eu).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mannheim Comprehensive Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- University of Leicester, United Kingdom.
- Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
- Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Förderung
- Generalitat de Catalunya
- Albert Einstein Cancer Center
- NIHR Leicester Biomedical Research Centre
- Manchester Biomedical Research Centre
- Associazione Italiana per la Ricerca sul Cancro
- Euratom Research and Training Programme
- Cancer Research UK
- Agencia Estatal de Investigación
Zitieren
APA
Bockstiegel, T., Webb, A., Aguado-Barrera, M. E., Aguado-Flor, E., Altabas, M., Aznar, M., Azria, D., Briers, E., Bultijnck, R., Chang-Claude, J., Cicchetti, A., De Santis, M. C., Dunning, A., Fachal, L., Fuentes-Rios, O., Giraldo, A., Gómez-Caamaño, A., Gutiérrez-Enríquez, S., Herskind, C., …, & Sperk, E. (2027). Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort. Clinical and Translational Radiation Oncology, 62, 101307. https://doi.org/10.1016/j.ctro.2026.101307
Vancouver
Bockstiegel T, Webb A, Aguado-Barrera ME, Aguado-Flor E, Altabas M, Aznar M, et al. Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort. Clinical and Translational Radiation Oncology. 2027;62:101307. doi:10.1016/j.ctro.2026.101307
BibTeX
@article{Bockstiegel2027,
author = {Bockstiegel, Tina and Webb, Adam and Aguado-Barrera, Miguel E and Aguado-Flor, Ester and Altabas, Manuel and Aznar, Marianne and Azria, David and Briers, Erik and Bultijnck, Renée and Chang-Claude, Jenny and Cicchetti, Alessandro and De Santis, Maria Carmen and Dunning, Alison and Fachal, Laura and Fuentes-Rios, Olivia and Giraldo, Alexandra and Gómez-Caamaño, Antonio and Gutiérrez-Enríquez, Sara and Herskind, Carsten and Heumann, Philipp and Johnson, Kerstie and Kaaks, Rudolf and Kerns, Sarah L and Lambrecht, Maarten and La Rocca, Eliana and Mollà, Meritxell and Rancati, Tiziana and Reyes, Victoria M and Romero, Juan Camilo Rosas and Rosenstein, Barry S and De Ruysscher, Dirk and Seibold, Petra and Shearer, Rebecca M and Stobart, Hilary and Symonds, R Paul and Taboada-Valladares, Begoña and Talbot, Christopher J and Vega, Ana and Veldeman, Liv and Veldwijk, Marlon R and Ward, Tim and West, Catharine M L and REQUITE/REQUITEplus/RADprecise consortia, REQUITE/REQUITEplus/RADprecise consortia and Rattay, Tim and Sperk, Elena},
title = {Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort},
journal = {Clinical and Translational Radiation Oncology},
year = {2027},
volume = {62},
pages = {101307},
doi = {10.1016/j.ctro.2026.101307}
}
EUVIMED